^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Apoptosis inhibitor

    Related drugs:
    1d
    Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy (clinicaltrials.gov)
    P=N/A, N=356, Recruiting, Children's Hospital of Fudan University | Trial completion date: Jul 2027 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    4d
    The Combination of Machine Learning and Metabolomics for the Clinical Diagnosis of Hepatocellular Carcinoma. (PubMed, J Proteome Res)
    Nontargeted and targeted metabolomic analyses were used to explore dysregulated metabolites, and many bile acids (such as DCA, GUDCA, GCDCA, GCA, TCDCA, TDCA, TCA, LCA, and TUDCA) and steroid hormones (such as DHEAS, DHEA, Aldo, Cortisone, and 18-OHF) were found to be dysregulated in HCC...It exhibited good diagnostic performance in the detection of early-stage and small-size HCC (AUC = 0.896 and AUC = 0.830) and performed better than the classical biomarker alpha-fetoprotein (AFP). In conclusion, our study established a novel XGBoost model based on bile acids and steroid hormones and might be helpful for the early diagnosis of HCC.
    Journal • Metabolomic study
    |
    AFP (Alpha-fetoprotein)
    8d
    Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 (clinicaltrials.gov)
    P3, N=39, Not yet recruiting, Polaryx Therapeutics, Inc. | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    17d
    ORION: AMX0035 and Progressive Supranuclear Palsy (clinicaltrials.gov)
    P2/3, N=139, Completed, Amylyx Pharmaceuticals Inc. | Active, not recruiting --> Completed | Trial completion date: Nov 2029 --> Oct 2025 | Trial primary completion date: Apr 2026 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date
    24d
    Impact of Ursodeoxycholic Acid on Clinical Outcomes in Patients with Acute Pancreatitis: A Randomized Controlled Trial (ChiCTR2600120559)
    P=N/A, N=60, The first affiliated hostipal of nanchang university; The first affiliated hostipal of nanchang university
    New trial
    24d
    Impact of Ursodeoxycholic Acid on Clinical Outcomes in Patients with Acute Pancreatitis: A Randomized Controlled Trial (ChiCTR2600119601)
    P1, N=60, The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University
    New P1 trial
    1m
    Chemical chaperone TUDCA rescues Insulin-mediated vascular relaxation via ER stress inhibition in diabetic rat model. (PubMed, Endocr Res)
    Insulin-mediated relaxation was impaired in diabetic rats (-56.7%) compared to controls (0%), accompanied by elevated ER stress markers and reduced eNOS, Akt, and IRS-1 expression. TUDCA treatment improved relaxation responses (-6.2%) significantly reduced ER stress markers and restored the expression of endothelial markers.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IRS1 (Insulin Receptor Substrate 1) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1) • NOS3 (Nitric oxide synthase 3) • PERK (Pancreatic EIF2-Alpha Kinase)
    1m
    GALPOL: Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution (clinicaltrials.gov)
    P=N/A, N=36, Active, not recruiting, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Feb 2026 --> Apr 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    1m
    HELIOS: AMX0035 in Adult Patients With Wolfram Syndrome (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Amylyx Pharmaceuticals Inc. | Trial completion date: Dec 2026 --> May 2028
    Trial completion date
    1m
    AVH: Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis (clinicaltrials.gov)
    P=N/A, N=88, Not yet recruiting, Combined Military Hospital, Pakistan
    New trial
    1m
    Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine. (clinicaltrials.gov)
    P2, N=69, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    1m
    MILK-HI-TUDCA: TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Peking University First Hospital
    New P2 trial